Matches in SemOpenAlex for { <https://semopenalex.org/work/W2526014735> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2526014735 endingPage "1075" @default.
- W2526014735 startingPage "1069" @default.
- W2526014735 abstract "Purpose Despite the documented success of IV to oral anti-infective conversion programs, it is still unclear what the current standard of practice is in the US. A survey was conducted to evaluate the prevalence and characteristics of conversion programs throughout the nation. Methods A questionnaire was mailed to 890 randomly chosen hospital pharmacy directors. A preset cutoff date of 4 weeks from the initial mailing was set for responses; a second mailing was sent to those directors that did not respond initially. Results A total of 237 (27%) institutions responded. Of these, 74% had instituted conversion programs. More programs required prior physician notification compared with allowing pharmacists to proactively transition candidates (70% vs 30%, P < 0.001). The most common anti-infectives converted were the fluoroquinolones and fluconazole. Common conversion criteria included adequate oral intake and fever reduction. Characteristics associated with an increased likelihood of a conversion program were pharmacy residency programs (RR 1.3; 95% CI 1.132 to 1.477), clinical pharmacists (RR 1.6; 95% CI 1.262 to 2.123), ID specialty pharmacists (RR 1.3; 95% CI 1.153 to 1.499), ID physician consult service (RR 1.2; 95% CI 1.028 to 1.459), and teaching hospitals (RR 1.2; 95% CI 1.038 to 1.386). Hospitals with conversion programs employed a greater number of clinical pharmacists (P = 0.02). Multivariate analysis revealed that the presence of a clinical pharmacist was the most significant variable predicting implementation (P < 0.001). Conclusion The majority of hospitals responding to this survey had an intravenous to oral conversion program. While most programs still required prior physician notification, the presence of clinical pharmacists significantly influenced the prevalence of implementation and proactive transition." @default.
- W2526014735 created "2016-10-07" @default.
- W2526014735 creator A5045141693 @default.
- W2526014735 creator A5066849207 @default.
- W2526014735 creator A5088741251 @default.
- W2526014735 creator A5090657231 @default.
- W2526014735 date "2004-11-01" @default.
- W2526014735 modified "2023-10-14" @default.
- W2526014735 title "IV to Oral Conversion Programs for Anti-Infectives in the United States: Prevalence and Characteristics" @default.
- W2526014735 cites W1574508660 @default.
- W2526014735 cites W2029762131 @default.
- W2526014735 cites W2037712857 @default.
- W2526014735 cites W2043273594 @default.
- W2526014735 cites W2046949207 @default.
- W2526014735 cites W2112323249 @default.
- W2526014735 cites W2168498122 @default.
- W2526014735 cites W2168593350 @default.
- W2526014735 cites W2298408365 @default.
- W2526014735 cites W2320270386 @default.
- W2526014735 cites W2342174064 @default.
- W2526014735 cites W2433846011 @default.
- W2526014735 cites W4236397645 @default.
- W2526014735 cites W4241931916 @default.
- W2526014735 doi "https://doi.org/10.1177/001857870403901108" @default.
- W2526014735 hasPublicationYear "2004" @default.
- W2526014735 type Work @default.
- W2526014735 sameAs 2526014735 @default.
- W2526014735 citedByCount "1" @default.
- W2526014735 crossrefType "journal-article" @default.
- W2526014735 hasAuthorship W2526014735A5045141693 @default.
- W2526014735 hasAuthorship W2526014735A5066849207 @default.
- W2526014735 hasAuthorship W2526014735A5088741251 @default.
- W2526014735 hasAuthorship W2526014735A5090657231 @default.
- W2526014735 hasConcept C10446079 @default.
- W2526014735 hasConcept C104863432 @default.
- W2526014735 hasConcept C126322002 @default.
- W2526014735 hasConcept C20387591 @default.
- W2526014735 hasConcept C2779457091 @default.
- W2526014735 hasConcept C38180746 @default.
- W2526014735 hasConcept C512399662 @default.
- W2526014735 hasConcept C71924100 @default.
- W2526014735 hasConceptScore W2526014735C10446079 @default.
- W2526014735 hasConceptScore W2526014735C104863432 @default.
- W2526014735 hasConceptScore W2526014735C126322002 @default.
- W2526014735 hasConceptScore W2526014735C20387591 @default.
- W2526014735 hasConceptScore W2526014735C2779457091 @default.
- W2526014735 hasConceptScore W2526014735C38180746 @default.
- W2526014735 hasConceptScore W2526014735C512399662 @default.
- W2526014735 hasConceptScore W2526014735C71924100 @default.
- W2526014735 hasIssue "11" @default.
- W2526014735 hasLocation W25260147351 @default.
- W2526014735 hasOpenAccess W2526014735 @default.
- W2526014735 hasPrimaryLocation W25260147351 @default.
- W2526014735 hasRelatedWork W2052892900 @default.
- W2526014735 hasRelatedWork W2054652734 @default.
- W2526014735 hasRelatedWork W2260182467 @default.
- W2526014735 hasRelatedWork W2391422502 @default.
- W2526014735 hasRelatedWork W2725236363 @default.
- W2526014735 hasRelatedWork W2749406675 @default.
- W2526014735 hasRelatedWork W2848508780 @default.
- W2526014735 hasRelatedWork W2954475304 @default.
- W2526014735 hasRelatedWork W3081988447 @default.
- W2526014735 hasRelatedWork W2949077388 @default.
- W2526014735 hasVolume "39" @default.
- W2526014735 isParatext "false" @default.
- W2526014735 isRetracted "false" @default.
- W2526014735 magId "2526014735" @default.
- W2526014735 workType "article" @default.